Navigation Links
ChanTest Awarded $1 Million Grant for Predictive Assays using Stem Cell-Derived Human Cardiomyocytes
Date:9/17/2012

CLEVELAND, Sept. 17, 2012 /PRNewswire/ -- ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant.  ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes. 

(Logo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO )

"This grant will allow us to optimize our industry-leading cardiomyocyte assays," said ChanTest's Principal Investigator Andrew Bruening-Wright, Ph.D.   "With our collaborators at FDA, DSEC, and Leadscope, Inc., we have improved predictivity models based on currently available ChanTest services.  Our nonclinical models will only get better as we fully integrate cardiomyocyte-based assays." 

These cardiomyocyte assays are critical for improving the predictivity of nonclinical testing and reducing the use of animals as proposed in the NIH roadmap for drug discovery and the FDA's critical path initiative.  The grant will also fund development of automated instrument-based services to increase throughput and drive down costs to meet the needs of ChanTest customers.

Dr. Arthur "Buzz" Brown, founder and CEO of ChanTest and co-PI on the grant, added "ChanTest has assembled an expert team to ensure success of this grant. We'll build on this success to improve drug discovery for other diseases in which ion channels play a critical role."

About ChanTest – The Ion Channel Expert

ChanTest's mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company's library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest's seminal role in the nonclinical cardiac safety field, along with the company's uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.

 

CONTACT: Chris Mathes, +1-732-586-1073

 


'/>"/>
SOURCE ChanTest
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ChanTest hires Chris Mathes as Chief Commercial Officer
2. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
3. QBC Diagnostics Awarded GSA Contract
4. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
5. Northwest Bio Awarded $5.5 Million German Government Grant
6. Nonin Medical Awarded Novation Contract for Clinically Proven Pulse Oximeters
7. Elsevier / Gold Standards Kay Morgan Awarded NCPCP Highest Honor
8. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
9. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
10. SurgiCount Medical Awarded Contract From HealthTrust Purchasing Group for the Safety-Sponge® System
11. Sorrento Therapeutics Awarded Third Phase I STTR Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, ... 8th Day Software and Consulting, LLC , and named ... 8th Day Software, based in Tennessee , ... 8th Day expands EnvoyHealth,s service offerings for health care ... "In an interoperable ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
Breaking Medicine News(10 mins):